The therapeutic effect on advanced clear cell renal cell carcinoma
To explore the efficacy of pazopanib, a molecular targeted drug for inhibiting angiogenesis and a tyrosine kinase inhibitor, in the treatment of advanced clear cell renal cell carcinoma. From June 2006 to May 2007, 14 outpatients from the General Hospital of the People's Liberation Army participated in the randomized clinical drug trial of pazopanib for advanced clear cell renal cell carcinoma. They were divided into the pazopanib group (10 cases) and the placebo group (4 cases), who received pazopanib at 800mg/day and placebo respectively. After 12 weeks of continuous treatment, The therapeutic effect is determined based on the CT examination results before and after taking the medicine.
The results showed that the average reduction ratios of measurable lesions in the pazopanib group and the placebo group were 27.6% and -2.8%, respectively (P < 0.05); The disease control rates of the pazopanib group and the placebo group were 100% and 25%, respectively. Conclusion: It is confirmed that the molecular targeted angiogenesis inhibitor tyrosine kinase inhibitor pazopanib can have a significant therapeutic effect on metastatic clear cell renal cell carcinoma in the short term and has high safety.
A phase III clinical study showed that pazopanib reduced the risk of tumor progression or death by 54% compared with placebo. Overall, the average progression-free survival (PFS) time of patients in this product group was 9.2 months, while that in the placebo group was 4.2 months. Among patients who had not received previous treatment, the average survival time of the product group was 11.1 months, and that of the placebo group was 2.8 months. Among patients who had previously received cytokine therapy, the average survival time in the pazopanib group was 7.4 months, and that in the placebo group was 4.2 months.
Audited Supplier 
){kind=link}